FDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)

FDA decision on BBP-418 in 2026 If the FDA's decision on BBP-418 by Ml Bio Solutions Inc. in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. BBP-418 (also known by its chemical name ribitol) is an experimental oral small-molecule drug being developed by BridgeBio to treat a rare inherited muscle dise